NANOSONICS LIMITED (NAN)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NAN

NAN - NANOSONICS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.58
Index: ASX200 | ASX300 | ALL-ORDS

Nanosonics is an Australian medical device company manufacturing high level disinfection systems to reduce the spread of infection. Founded in 2001, the company listed on the ASX in 2007.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$3.92

11 Jul
2025

-0.030

OPEN

$3.95

-0.76%

HIGH

$3.99

289,450

LOW

$3.91

TARGET
$4.663 18.9% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
NAN: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 4.3 6.2 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx - 35.2% 44.9% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 63.2 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx4.3
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx171.6 M
Book Value Per Share xxxxxxxxxxxxxxx60.1
Net Operating Cash Flow xxxxxxxxxxxxxxx22.8 M
Net Profit Margin xxxxxxxxxxxxxxx7.56 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx7.50 %
Return on Invested Capital xxxxxxxxxxxxxxx7.21 %
Return on Assets xxxxxxxxxxxxxxx5.54 %
Return on Equity xxxxxxxxxxxxxxx7.50 %
Return on Total Capital xxxxxxxxxxxxxxx4.58 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx20.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx3 M
Long Term Debt xxxxxxxxxxxxxxx6 M
Total Debt xxxxxxxxxxxxxxx9 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx130 M
Price To Book Value xxxxxxxxxxxxxxx4.97

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx2.5 M
Capex % of Sales xxxxxxxxxxxxxxx1.47 %
Cost of Goods Sold xxxxxxxxxxxxxxx44 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx119 M
Research & Development xxxxxxxxxxxxxxx30 M
Investments - Total xxxxxxxxxxxxxxx1 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.1

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

5

xxxxxxxxx xx xxxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

21/03/2025

1

Add

$5.50

40.31%

With the much-anticipated approval for Nanosonics' flexible endoscope Coris received from the FDA, Morgans stresses the sizeable market opportunity for the flexible endoscope, given the company's advantages over the competition.

The analyst raises the target price to $5.50 from $4.50 with the de-risking of FDA approval.

Morgans believes Nanosonics remains a "key stock to watch" with an Add rating. Earnings forecasts from the broker are unchanged, as expectations for Coris had already been included.

FORECAST
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of 6.00 cents.
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of 9.00 cents.

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Wilsons

27/04/2025

1

Overweight

$6.00

53.06%

Following a site tour of Nanosonics' facilities to see the Coris system in operation, Wilsons believes the product could get 2-3 times higher average selling price than initially assumed.

The broker also thinks its assumption for the Quantum consumable pricing revenue is on the conservative side.

The analyst reiterated Coris would become earnings before interest and tax positive in a few years and the current share pricing only factors 50% of the value.

Overweight. Target unchanged at $6.

FORECAST
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of 5.40 cents.
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of 4.70 cents.
Access Extra Coverage Research History >

NAN STOCK CHART

FNArena News on NAN

1
Rudi’s View: Gold stocks & Miners, DigiCo, Pinnacle & More

Jul 10 2025 - Rudi's View
2
Australian Broker Call *Extra* Edition – Jul 07, 2025

Jul 07 2025 - Daily Market Reports
3
In Brief: Austal, Superloop, Motorcycle Holdings & Nanosonics

Jul 04 2025 - Weekly Reports
4
Rudi’s View: Charter Hall, Droneshield, Pinnacle, WiseTech & More

Jul 03 2025 - Rudi's View
5
Rudi’s View: ANZ, Aurizon, Cochlear, Newmont, Telix & More

Jun 26 2025 - Rudi's View

Latest Medical Equipment & Devices News

1
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia
2
Cochlear Downgrades Ahead Of New Launches

Jun 19 2025 - Australia
3
Fisher & Paykel Healthcare’s Tariffs Annoyance

Jun 04 2025 - Australia
4
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
5
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
6
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
7
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
8
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia
9
The Trend Remains Pro Medicus’ Friend

Jan 16 2025 - Technicals
10
Diagnostic Imaging Radiates Opportunity

Dec 18 2024 - Small Caps